Evidence map›Paper›PMID 35590222›Full record

ArticleMed (New York, N.Y.)2021

Vaccination for IDH-mutant tumors: A novel therapeutic approach applied to glioma.

David A Reardon, Michael Weller

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Med (New York, N.Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

David A ReardonCenter for Neuro-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, D2134, Boston, MA 02115-5450, USA. Electronic address: david_reardon@dfci.harvard.edu.
Michael WellerDepartment of Neurology and Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland. Electronic address: michael.weller@usz.ch.
Dana-Farber Cancer Institute · USUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In a recent Nature publication, Platten et al. describe the feasibility, safety, immunogenicity, and encouraging efficacy of a vaccine targeting the IDH1 R132H protein among newly diagnosed patients with IDH1-mutant glioma. These findings raise promising therapeutic ramifications for the spectrum of IDH1/2-driven tumors.

Indexed as

GliomaIsocitrate DehydrogenaseHumansMutationVaccinationIsocitrate Dehydrogenase

Identifiers

PMID35590222
OpenAlexW3162454602

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.